Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed...
3 KB (212 words) - 21:08, 11 November 2023
proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
5 KB (305 words) - 05:22, 23 October 2024
proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
49 KB (6,232 words) - 07:00, 22 October 2024
compound solution of sodium lactate (INN) Compro Comtan Comtrex Comvax conatumumab (USAN, INN) conbercept (INN) Concentraid Conceptrol Concerta condoliase...
7 KB (421 words) - 02:51, 27 September 2024
humanized PTK7 cancer Coltuximab ravtansine mab chimeric CD19 cancer Conatumumab mab human TRAIL-R2 cancer Concizumab Alhemo mab humanized tissue factor...
137 KB (4,083 words) - 21:25, 19 October 2024
proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
8 KB (316 words) - 13:53, 10 September 2024
proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
8 KB (501 words) - 13:55, 10 September 2024
proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
24 KB (2,809 words) - 11:12, 20 August 2024
proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
12 KB (1,387 words) - 13:47, 4 September 2024
proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
20 KB (2,146 words) - 16:24, 21 August 2024
proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
12 KB (1,459 words) - 03:14, 30 October 2022
proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
12 KB (1,508 words) - 17:56, 19 August 2022
proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
12 KB (1,494 words) - 19:35, 4 September 2024
Atezolizumab (+hyaluronidase) Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab vedotin...
5 KB (368 words) - 15:29, 21 August 2024
Atezolizumab (+hyaluronidase) Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab vedotin...
4 KB (241 words) - 13:42, 14 July 2024
Atezolizumab (+hyaluronidase) Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab vedotin...
3 KB (129 words) - 01:04, 19 July 2023